QUANTUM BIOPHARMA-B SUB VOT
QNTMNASDAQTrading Snapshot
- Day Range
- $3.80 – $3.84
- 52-Week Range
- $2.07 – $19.30
- Volume
- $2.90B
- Avg Volume
- $2.80B
- Shares Outstanding
- 6.4M
- Next Earnings
- Nov 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $6M
- Last Q Revenue
- $2M
- P/E Ratio
- -0.7
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-3.74
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +278.4%
Why Investors Own QNTM
- ✓High-growth profile — revenue up +10.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 47% gross margin and 22% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
QUANTUM BIOPHARMA-B SUB VOT
QNTM
StockOtter · stockotter.spaceAbout QUANTUM BIOPHARMA-B SUB VOT
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
QUANTUM BIOPHARMA-B SUB VOT tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift QNTM price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
QUANTUM BIOPHARMA-B SUB VOT announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.